P3 Health Partners Inc. — Form 10-Q Summary
Period clarification: The request identifies 2022 Q1, but the filing is for the three months ended March 31, 2023, with comparisons to Q1 2022. Amounts below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Business context and reporting period
P3 is a physician-led population health management company that primarily accepts financial risk under capitated contracts for Medicare Advantage members. At March 31, 2023, its network included approximately 2,800 affiliate primary care physicians across 15 markets in five states and served approximately 103,400 at-risk members. Capitated payments represented about 99% of quarterly revenue.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Total revenue | $302.1 | $273.5 |
| Operating loss | $(48.8) | $(52.2) |
| Net loss | $(52.4) | $(60.8) |
| Net loss attributable to controlling interests | $(9.2) | $(10.6) |
| Adjusted EBITDA loss (non-GAAP) | $(19.1) | $(18.9) |
| Cash used in operating activities | $(23.7) | $(27.8) |
- Revenue increased 10%, including capitated revenue growth of 11% to $298.7 million. Management attributed the increase to 3% more at-risk members and a 7% rise in capitated rates, associated with higher average member acuity.
- Medical expense was $285.6 million, up 7%. The company reported a $5.1 million premium deficiency reserve expense, versus a $1.3 million benefit in Q1 2022. Management attributed the reserve change to its assessment of expected future losses.
- Company-defined medical margin was $39.2 million versus $24.8 million; network contribution was $16.5 million versus $7.7 million. Both are non-GAAP measures. GAAP operating loss remained substantial.
- Interest expense rose 48% to $4.1 million, primarily due to the VGS unsecured note. The Q1 2023 results also included a $0.6 million warrant mark-to-market gain, compared with a $5.9 million loss in Q1 2022.
- Cash and restricted cash totaled $8.4 million at quarter-end, including $7.2 million unrestricted cash. Net cash declined $10.1 million during the quarter. The balance sheet showed $269.7 million of current liabilities and $108.1 million of long-term debt, net; stockholders’ equity was negative $2.7 million, alongside $473.7 million of redeemable non-controlling interests.
- Debt included a $65.0 million term loan at 12%, a $29.1 million VGS note at 14%, and a $15.0 million repurchase note at 11%. The company reported covenant compliance at March 31, but gave no assurance of future compliance.
Material changes and subsequent financing
- At-risk membership increased from approximately 100,000 to 103,400 year over year; affiliate PCPs increased from approximately 2,200 to 2,800.
- Medical expense growth was partly attributed to participation in the ACO REACH model, which began January 1, 2023, and was partly offset by termination or conversion of certain health plans from at-risk to upside-only risk.
- Corporate, general and administrative expense fell 2% to $37.6 million. Lower equity-based compensation was partly offset by higher public-company professional fees and salary-related costs. Platform support costs increased to $30.5 million from $22.6 million and rose to 10% of revenue from 8%.
- After quarter-end, on April 6, 2023, P3 completed a private placement for approximately $89.5 million gross proceeds. It issued approximately 69.2 million Class A shares and warrants to purchase approximately 59.9 million shares, plus pre-funded warrants for approximately 10.8 million shares. The financing provides capital but is potentially highly dilutive; the filing does not present a post-transaction cash balance.
Outlook, risks, contingencies, and unusual items
- Going concern: Management stated that existing cash resources were insufficient to support planned operations for at least one year from filing issuance and that substantial doubt existed about the company’s ability to continue as a going concern. It expected continued operating losses and negative operating cash flows and said additional capital may be needed. The April financing occurred after quarter-end, but management’s stated assessment did not incorporate the potential mitigating effect of capital-raising efforts not fully implemented at the time of its evaluation.
- No quantified operating guidance: The filing provides no formal revenue, earnings, or cash-flow guidance. Management described expected continued investment and losses, while identifying membership growth, medical-cost control, member maturity, and access to capital as important drivers.
- Claims and contract risk: Claims payable were $164.9 million and the premium deficiency reserve was $31.5 million at March 31. Estimates of incurred claims and future contract losses can materially affect results. Four health plan customers each represented at least 10% of revenue and collectively accounted for 61% of Q1 revenue.
- Debt and capital risk: Debt covenants include minimum liquidity and revenue requirements, with stated annual revenue thresholds of $525 million for 2023, $585 million for 2024, and $650 million for 2025. Failure to obtain financing or meet covenants could constrain operations; the company noted potential dilution and restrictive financing terms.
- Internal controls: Management concluded disclosure controls were ineffective at March 31 due to continuing material weaknesses in the control environment, risk assessment, IT controls, financial close and review controls, and claims estimation. Remediation was ongoing, with no assurance the measures would fully resolve the weaknesses.
- Other items: A $5.0 million health-plan settlement remained unpaid and recorded in settlements payable. A books-and-records action was dismissed with prejudice in May 2023; a separate Hudson dispute had surviving claims in discovery. The company also disclosed an April 2023 business-email-compromise fraud attempt that caused no material loss.
Important facts for investors to verify
- Confirm the period: this filing reports Q1 2023, not Q1 2022.
- Assess liquidity after the April private placement, including net proceeds, cash use since closing, and the resulting fully diluted share and warrant count.
- Track operating cash burn, unrestricted cash, claims development, premium deficiency reserves, and the company’s ability to satisfy debt covenants and revenue thresholds.
- Evaluate whether membership and revenue growth translate into sustainable GAAP profitability, given the adjusted EBITDA loss and ongoing operating losses.
- Review progress remediating material weaknesses and any subsequent developments in the Hudson litigation and health-plan settlement.